Propanc Biopharma Inc

PPCB Healthcare Biotechnology

EPS
−99.6%
Free cash flow
−1,637.4%
Total debt
−21.4%

Quarter to June 2026, against a year earlier

1.79 0.15 +9.15%
Market cap
$1.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22 Jun '23 Jun '24 Jun '25 Jun '26
Current Ratio
0.01 0.01 0.02 0.02 0.00 0.00 0.01 0.01 1.50 2.55
Net Debt/EBITDA
0.00 (0.01) (0.02) 0.00 (0.03) (0.02) (0.06) (0.20) (0.01) 0.02
Debt/Equity
(0.01) (0.01) (0.01) (0.01) (0.02) (0.02) (0.04) (0.09) 0.04 0.05
ROE
196.27% 115.36% 104.10% 119.22% 71.97% 110.09% 101.75% 58.39% (1,163.68%) (169.86%)
ROA
(3,318.22%) (8,455.50%) (6,653.26%) (4,735.96%) (4,332.80%) (7,085.23%) (4,403.94%) (3,034.66%) (598.08%) (122.15%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (247.22%) (125.86%)
Return on Tangible Assets
144.52% 104.22% 133.81% 129.34% 78.76% 110.26% 99.61% 53.09% (2,123.67%) (381.25%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.58) (55.27) (3.93) (75.19) (0.38) (21.06) (0.64) 0.00 (25.48) (50.60)
Book value per Share
(1.55) (171.37) (8.19) (148.02) (1.01) (44.33) (1.79) 0.00 874.60 83.65
Free Cash Flow
(2.05) (2.18) (2.06) (1.85) (1.15) (1.44) (1.11) (0.94) (0.41) (5.69)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026